SECsense Logo

Vistagen Therapeutics, Inc. Form 8-K Report: Key Insights and Updates

$VTGN
Form 8-K
Filed on: 2025-01-13
Source
Vistagen Therapeutics, Inc. Form 8-K Report: Key Insights and Updates

Based on the provided XML section from a financial report, here are the key pieces of information extracted:

  1. Entity Information:
  • Company Name: Vistagen Therapeutics, Inc.
  • CIK Number: 0001411685
  • Company Identifier: 000-54014
  • Employer Identification Number (EIN): 20-5093315
  • Address: 343 Allerton Ave., South San Francisco, CA 94080
  • Phone Number: 650-577-3600
  1. Report Type and Filing Date:
  • Filing Type: Form 8-K
  • Filing Date: January 10, 2025
  1. Stock Information:
  • Common Stock Par Value: $0.001 per share
  • Ticker Symbol: VTGN
  • Exchange: NASDAQ
  1. Reporting Period:
  • Start Date: September 23, 2024
  • End Date: September 23, 2024
  1. Additional Metadata:
  • The document is in XBRL format, indicating it is likely meant for digital filing and analysis.
  • The XML declaration indicates the document is encoded in UTF-8.

Insights:

  • The report is a Form 8-K, typically used to announce major events that shareholders should know about. The specific details of the event are not included in the extracted section.
  • The reporting date is quite close to the filing date, suggesting the company may be disclosing timely information.
  • The company is publicly traded on NASDAQ, which may indicate a higher level of scrutiny and regulatory compliance.
  • The common stock has a low par value, which is typical for many companies, often reflecting the company's growth stage or capital structure strategy.

This analysis highlights the fundamental aspects of the company and the nature of the report, which could be useful for investors or stakeholders monitoring Vistagen Therapeutics, Inc.